During the renewal of the skeleton, type 1 procollagen’s amino- and carboxy-terminal regions are cleaved by specific proteases during its conversion to collagen and subsequent incorporation into bone matrix. The presence of these N-terminal extension propeptides, known as type 1 procollagen amino terminal peptides (P1NP), therefore reflects the deposition of collagen and can be defined as a marker of bone formation. P1NP is released into the blood stream during type 1 collagen formation. Elevated levels are found in patients with increased bone turnover. It is specifically used for monitoring of bone formation during anabolic therapy.
Assessing treatment response and compliance to osteoporosis therapy (such as bisphosphonates), but specifically the response to treatment by human PTH (Teriparatide).
|:|| 15.1-58.6 ng/mL.
The least significant change for serum P1NP is ±25 %, with a reasonable response to hPTH therapy being an increase of at least ≥40 % (a very good response to therapy being an increase of between 100-200 %). Note that post-menopausal reference ranges are poorly defined. A post-menopausal reference range is available on request and is suitable for research studies only.
SST (gold top), EDTA (lavender top) or heparin (green top). Samples can be stored at 4 ºC for up to 1 week, or at -20 ºC for longer storage.
If monitoring the response to treatment, the sample should be collected at the same time of day.